Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel was superior to intravenous paclitaxel plus intravenous cisplatin. In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plu...
Saved in:
Published in | The New England journal of medicine Vol. 354; no. 1; pp. 34 - 43 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston, MA
Massachusetts Medical Society
05.01.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel was superior to intravenous paclitaxel plus intravenous cisplatin.
In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel was superior to intravenous paclitaxel plus intravenous cisplatin.
Ovarian cancer is the leading cause of death from a gynecologic cancer in the United States.
1
In most cases, the high death rate is due to tumor that has spread beyond the ovary at the time of diagnosis.
2
In the United States, the standard chemotherapy for the initial treatment of ovarian cancer is a combination of a platinum analogue with paclitaxel.
3
,
4
With modern surgical interventions and contemporary chemotherapy, most patients attain complete clinical remission.
3
,
5
The majority of them, however, will eventually have a relapse and die of the disease.
The peritoneal cavity is the principal site of disease . . . |
---|---|
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMoa052985 |